Circulating Endothelial Cells in Neuroendocrine Tumors
Abstract #757

Introduction: Circulating endothelial cells (CECs) are mature endothelial cells that are shed into the bloodstream. We hypothesised that neuroendocrine tumors (NETs), being highly vascular, may shed more CECs into the circulation, and that changes in their number may serve as a biomarker for anti-angiogenic therapy.

Aim(s): To compare the number of CECs in NET patients with that of healthy controls.

Materials and methods: Whole blood (4mls) was collected from healthy controls and patients with a diagnosis of metastatic NET. CECs were characterized morphologically and by the co-expression DAPI+CD105+CD45- and enumerated using the Cellsearch™ system. Intersample variability was assessed in a sub-group of controls and patients.

Further abstracts you may be interested in

Introduction: We have previously demonstrated that Circulating Tumor Cells (CTCs) can be detected in patients with neuroendocrine tumors (NET) and that their presence is prognostic. Downstream analysis of CTCs provides an opportunity to explore their potential as biomarker for targeted therapy. Here we present initial data which demonstrates that molecular profiling can be successfully performed on single CTCs from patients with NETs

Introduction: Several guidelines have given recommendations for optimal use of biomarkers and molecular imaging. However, those guidelines’ implementation may not be always possible due to local policies or lack of access to several diagnostic studies.

Introduction: Bone metastases have been described in up to 32% of NET patients and are associated with a worse clinical outcome. Overexpression of CXCR4 in primary tumors appears predictive of skeletal involvement.

To continuously improve user experience - only with your consent - your data will be transmitted to Google Analytics. You can find out all relevant information on the use of cookies in our privacy policy.